Cidara Therapeutics, Inc. (CDTX)

Over the past six months, several events have significantly impacted Cidara Therapeutics' stock price. Cidara announced positive top-line results from its Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza. The company closed an upsized public offering, generating gross proceeds of $402.5 million. Cidara was added to the Russell 2000® and Russell 3000® Indexes. Cidara announced an expanded and accelerated Phase 3 development plan for CD388. Cidara received an award valued up to $339 million from BARDA to support expanded manufacturing and clinical development of CD388. Cidara presented promising data on CD388 at the European Scientific Working Group on Influenza (ESWI) 10th Influenza Conference. The company's stock price saw a remarkable increase of 761.65% from October 24, 2024, to October 23, 2025. Analysts have generally issued "Moderate Buy" ratings for CDTX, with an average 12-month price target of $151.33. In the past three months, Cidara Therapeutics insiders have sold $29,796.00 in company stock.

Demand seasonality for Cidara Therapeutics' products is evident, particularly for its lead candidate CD388, which is designed for the prevention of seasonal and pandemic influenza. The Phase 3 study for CD388 is scheduled to begin enrollment in the Northern Hemisphere in the fall of 2025 and continue into the spring of 2026 in the Southern Hemisphere, aligning with the typical flu seasons in these regions. This indicates that the demand for such a preventative therapeutic would naturally fluctuate with the prevalence of influenza during specific times of the year.

Cidara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting anti-infectives and immunotherapies. The company utilizes its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs). The company's major products and pipeline candidates include Rezafungin, a once-weekly intravenous echinocandin antifungal in late-stage development, and CD388, a long-acting antiviral DFC designed for universal prevention and treatment of seasonal and pandemic influenza with a single dose. Cidara is also investigating other Cloudbreak immunotherapeutic candidates for oncology and viral infections.

Cidara Therapeutics, Inc. is headquartered in San Diego, California, USA. The planned Phase 3 study for its influenza preventative candidate, CD388, is a global, multicenter trial.

Cidara Therapeutics' brand reputation in the past year has seen a building momentum, largely driven by positive clinical developments. The company has been described as "one of the most talked-about names in biotech this year" due to robust Phase 2b trial data for CD388 and its FDA Breakthrough Therapy designation. However, its news sentiment score is 0.49, which is lower than the average news sentiment score of 0.82 for Medical companies. Despite this, analyst ratings are generally positive, with a consensus of "Moderate Buy".

Cidara Therapeutics, Inc. has a mixed ownership structure comprising institutional, insider, and retail investors. The company has 199 institutional owners holding a total of 26,854,925 shares. Ag Mundipharma is reported as the largest individual shareholder, owning 4.78 million shares, representing 36.87% of the company.